MaxCyte, Inc.
9713 Key West Ave., Suite 400
Rockville
Maryland
20850
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
216 articles about MaxCyte, Inc.
-
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer
9/9/2020
Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectors
-
CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11
8/18/2020
New parallel cohort will broaden evaluation of MCY-M11 in patients through inclusion of a preconditioning regimen and multiple dosing cycles
-
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
7/8/2020
APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials
-
MaxCyte® Initiates Launch of New ExPERT™ Range of Expanded Research and GMP Grade Disposables for Complex Cellular Engineering
6/25/2020
Enhanced range of volumes and design features will support expanded use in both cell therapy drug development and early drug discovery
-
MaxCyte to Present at 2020 European Biotech Investor Day
6/22/2020
MaxCyte, a global cell-based therapies and life sciences company, announced that CEO Doug Doerfler plans to present an overview of the company and provide a business update at the 2020 European Biotech Investor Day, co-hosted by Solebury Trout with Nasdaq, Deutsche Bank and Goodwin.
-
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
5/18/2020
MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the American Society of Clinical Oncology's upcoming annual meeting.
-
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
5/7/2020
- Agreement enables Caribou to utilize MaxCyte's ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs
-
MaxCyte Provides Business Update Related to COVID-19 Pandemic
4/9/2020
Dosing of fourth cohort initiated according to plan in Phase I clinical trial of lead CARMA therapy candidate, MCY-M11
-
BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.
-
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
3/24/2020
Agreement enables Allogene, a pioneer in the development of AlloCAR T™ therapies for cancer, to utilize MaxCyte's ExPERT™ platform in target candidates
-
MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update
12/19/2019
MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that Shruti Abbato has joined the Company as Executive Vice President, Business Development for CARMA Cellular Therapies
-
MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs
12/4/2019
MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement.
-
MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients
10/24/2019
CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential
-
MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology
10/23/2019
MaxCyte, the global cell-based therapies and life sciences company, announces two presentations at the 5th Annual Cell & Gene Therapy Congress taking place 29-30 October in London, UK, which showcase the Company’s cell therapy technology.
-
MaxCyte Announces Presentation at ICLE 2019
9/9/2019
MaxCyte announces that Director of Field Applications Scientists Christopher Mann, PhD, will present on “Advancing Adoptive Cellular Therapies Using Non-viral-based Engineering” at the 2nd International Conference on Lymphocyte Engineering on Saturday 14 September at 9:50 a.m. BST.
-
MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention
5/29/2019
MaxCyte announced that Doug Doerfler, Chief Executive Officer, will provide a company overview at the 2019 BIO International Convention on Wednesday, June 5, at 1:15 p.m. ET at the Pennsylvania Convention Center in Philadelphia.
-
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
5/8/2019
No dose-limiting toxicities or safety concerns observed in first cohort of treated patients
-
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
-
MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
5/1/2019
CARMA drug candidates can be manufactured via streamlined, single-day process, providing a much needed faster turnaround of autologous cell therapy to patients
-
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.